Oncotarget is a peer-reviewed, open-access biomedical journal indexed in MEDLINE, PubMed, PMC, Scopus, and more.
Orchard Park, NY
Joined February 2016
- Tweets16.3K
- Following3.7K
- Followers3.4K
- Likes6.8K
Pinned Tweet
🔬 Scientific integrity is at the core of scholarly publishing.
A new editorial from Oncotarget highlights publishing industry trends, measurable journal comparisons, and future strategy.
🔗 doi.org/10.18632/oncotarget.…
#ScientificIntegrity #AcademicPublishing #OA #Research
ALT Figure 4: Post-tools era. Oncotarget versus Scientific Reports and PLOS One. The percentage of “High risk” articles identified by the tool “Argos” (as of 3/05/2026) in relation to the total number of articles published in a journal during a specific year in 2019–2025.
📰 Stay updated with the latest #Oncotarget announcements and #PressReleases:
oncotarget.com/news/pr/
#OA #PeerReviewed #Oncology #Cancer #Research
✅ Read a #blog summary about the #research paper, titled "Effect of TIMPs and their minimally engineered variants in blocking invasion and migration of brain cancer cells."
#Summary ⬇️
oncotarget.org/2025/05/21/en…
#cancer #glioblastoma #braincancer #oa
🔎 Over 26,000 Oncotarget papers are now searchable on #PubMed:
pubmed.ncbi.nlm.nih.gov/?ter…
#publishing #cancer #research #openaccess #peerreviewed #journalpublication
🎥 #OncotargetShort:
Abstract #video about the #editorial, titled "Tumor infiltrating lymphocyte (TIL) therapy for treating the solid tumors: Challenges and future perspectives." @mgumstjpr
🔗 bit.ly/4oG8f4n
#cancer #PaperSpotlight #lymphocytes #immunotherapy #tumors
🔆 #PaperSpotlight:
This #editorial was #published in Volume 17, titled "Tumor infiltrating lymphocyte (TIL) therapy for treating the solid tumors: Challenges and future perspectives."
#PressRelease ⬇️
oncotarget.net/2026/06/22/tu…
#immunotherapy #tumor #lymphocytes #oa #publishing
📅 Follow past and upcoming #Conferences where Oncotarget #Sponsors or presents:
oncotarget.com/news/conferen…
#Cancer #Oncology #Research #Publishing #Meetings #OpenAccess #Oncotarget
Oncotarget retweeted
#PaperoftheDay: "A novel RNA- based approach to counteract EMT"
DOI ⬇️
doi.org/10.18632/oncoscience…
#Cancer #Oncology #Research #OpenAccess #Publishing #PeerReviewed #Journal
#PaperoftheDay: "Artificial intelligence in nutritional oncology: From isolated screening tools to agentic intervention systems"
DOI ⬇️
doi.org/10.18632/oncotarget.…
#Cancer #Oncology #OpenAccess #Research #Publishing #PeerReviewed #Journal
🫁 Explore Oncotarget’s Special Collection on Lung Cancer:
oncotarget.com/collections/l…
#lungcancer #cancerresearch #collections #publishing #openaccess #cancer
📈 #TrendingWithImpact:
“Case Report WIN-MTB-2024001 – WIN International Molecular Tumor Board: A 55-year-old male with glioblastoma exhibiting amplifications in MDM2 and EGFR” @BrownUniversity
🔗 bit.ly/4BifOUy
#Cancer #Quote #Glioblastoma #Oncotarget ##CaseReport
🎧 Listen to our #PressRelease on the #CaseReport "Case Report WIN-MTB-2024001 – WIN International Molecular Tumor Board: A 55-year-old male with glioblastoma exhibiting amplifications in MDM2 and EGFR."
soundcloud.com/oncotarget/in…
#Cancer #Podcast #Audio #SoundCloud #Glioblastoma
🎥 #OncotargetShort:
Abstract #Video about the #CaseReport "Case Report WIN-MTB-2024001 – WIN International Molecular Tumor Board: A 55-year-old male with glioblastoma exhibiting amplifications in MDM2 and EGFR." @BrownUniversity
🔗 bit.ly/4BifOUy
#Cancer #Glioblastoma
📈 #TrendingWithImpact:
"Case Report WIN-MTB-2024001 – WIN International Molecular Tumor Board: A 55-year-old male with glioblastoma exhibiting amplifications in MDM2 and EGFR"
#PressRelease ⬇️
bit.ly/4iboH9E
#Cancer #Glioblastoma #CaseReport #OA #Oncotarget #Press
🛡️ To maintain scientific integrity and reduce the risk of costly settlements related to image fraud, we recommend institutions subscribe to image forensics tools, establish dedicated image forensics teams, and encourage researchers to screen their manuscripts before publication.
ALT Oncotarget Scientific Integrity
#PaperoftheDay: "Small bowel GIST harboring concurrent KIT exon 9 duplication and SDHC mutation: A case report"
DOI ⬇️
doi.org/10.18632/oncotarget.…
#Cancer #Oncology #OpenAccess #Research #Publishing #PeerReviewed #Journal
✅ Could PD-1/PD-L1 inhibitors improve outcomes for patients with high-risk solid tumors?
A new meta-analysis examined the efficacy and safety of immune checkpoint inhibitors as adjuvant cancer therapies.
#Summary ⬇️
oncotarget.org/2026/05/20/im…
#cancer #immunotherapy #research #oa
🌐 Visit Oncotarget.org to read #blog synopses of new and #trending #research papers published by Oncotarget.
#openaccess #peerreviewed #oncology #cancer #researchpapers #science #medicine #medEd #OA
📘 #Editors, #authors & #reviewers:
Follow ethical best practices and ICMJE’s guidelines for conducting, reporting, and publishing medical research: icmje.org/recommendations/
#cancer #research #science #OA #ebm
Oncotarget retweeted
📈 #TrendingWithImpact:
"Stevens–Johnson syndrome following combination therapy with pembrolizumab and enfortumab vedotin in a patient with metastatic urothelial carcinoma: A rare but serious adverse event"
#PressRelease ⬇️
bit.ly/3Ugxb7J
#UrothelialCancer #Oncoscience
🔎 Over 26,000 Oncotarget papers are now searchable on #PubMed:
pubmed.ncbi.nlm.nih.gov/?ter…
#publishing #cancer #research #openaccess #peerreviewed #journalpublication